Subscribe To
Alpine immune sciences: november 2023 data release could get ball rolling
Preliminary clinical data from the Alpine Immune Sciences, Inc. ongoing phase 3 RUBY-3 study will be presented at the American Society of Nephrology A...
October 6, 2023, 3:31 pm
In a push to limit use of glucocorticoids, us and eu5 rheumatologists are increasingly turning to gsk’s benlysta and astrazeneca’s saphnelo for the treatment of moderate-to-severe systemic lupus eryth
Despite overall biologic growth in both geographies, use of advanced systemic treatments in the US outpaces the EU5. Exton, Pennsylvania, Oct. 04, 202...
October 4, 2023, 7:00 am
Horizon's (hznp) daxdilimab fails to meet goal in lupus study
Horizon (HZNP) fails to meet the primary endpoint in the mid-stage study of evaluating daxdilimab in the treatment of systemic lupus erythematosus....
July 24, 2023, 12:20 pm
Immupharma presses on with next phase of lupuzor clinical trials
ImmuPharma PLC (AIM:IMM, OTC:IMMPF) is set to initiate a Phase 2/3 adaptive clinical trial for its P140 (Lupuzor) drug in systemic lupus ...
June 19, 2023, 4:11 am
Immupharma partner gets fda meeting date
ImmuPharma PLC (AIM:IMM, OTC:IMMPF) has confirmed a Type-C meeting is scheduled with the US Food & Drug Administration for June 7. Scientists will di...
April 19, 2023, 2:28 am
Immupharma: us partner has submitted lupuzor phase ii/iii trial protocol
ImmuPharma PLC (AIM:IMM, OTC:IMMPF) has said its partner Avion Pharmaceuticals has submitted the phase II/III clinical protocol for Lupuzor to the Fo...
March 27, 2023, 2:51 am
Abbvie (abbv) provides clinical updates on inflammatory drugs
AbbVie???s (ABBV) two studies evaluating Skyrizi in ulcerative colitis and Rinvoq in systemic lupus erythemato...
March 24, 2023, 2:28 pm
Why is nektar therapeutics (nktr) stock down 39% today?
Nektar Therapeutics (NASDAQ: NKTR ) stock is taking a beating on Friday following the release of Phase 2 clinical trial data. This Phase 2 study had N...
February 24, 2023, 8:56 am
Immupharma partner agrees phase ii/iii clinical trial process
ImmuPharma PLC (AIM:IMM, OTC:IMMPF) said partner Avion Pharmaceuticals is to launch an adaptive phase II/III clinical study on Lupuzor, the former's d...
February 6, 2023, 2:18 am
Astrazeneca's (azn) lupus drug saphnelo gets europe nod
AstraZeneca's (AZN) Saphnelo is the only new biologic to be approved in Europe in over a decade for patients with systemic lupus erythematosus....
February 17, 2022, 12:19 pm
Astrazeneca's (azn) lupus drug saphnelo gets europe nod
AstraZeneca's (AZN) Saphnelo is the only new biologic to be approved in Europe in over a decade for patients with systemic lupus erythematosus....
February 17, 2022, 12:19 pm
Astrazeneca's (azn) lupus drug saphnelo gets europe nod
AstraZeneca's (AZN) Saphnelo is the only new biologic to be approved in Europe in over a decade for patients with systemic lupus erythematosus....
February 17, 2022, 12:19 pm
Astrazeneca eu wins approval for the first drug in more than a decade for lupus
AstraZeneca PLC (LSE:AZN) has received EU approval for the first new drug in over a decade for people with systemic lupus ...
February 16, 2022, 2:33 am
Astrazeneca eu wins approval for the first drug in more than a decade for lupus
AstraZeneca PLC (LSE:AZN) has received EU approval for the first new drug in over a decade for people with systemic lupus ...
February 16, 2022, 2:33 am
Astrazeneca eu wins approval for the first drug in more than a decade for lupus
AstraZeneca PLC (LSE:AZN) has received EU approval for the first new drug in over a decade for people with systemic lupus ...
February 16, 2022, 2:33 am